VANCOUVER, Canada — October 7, 2026
Clearmind Medicine announced that it has submitted recommendations to the U.S. Food and Drug Administration (FDA) in response to the agency’s public hearing and request for comments concerning the potential future therapeutic use of psychedelic drugs. The company’s submission focuses on the development and patient access potential of psychedelic-derived, non-hallucinogenic neuroplastogens, particularly for alcohol use disorder (AUD) and other underserved neuropsychiatric conditions. Clearmind said its recommendations are intended to contribute to the regulatory discussion surrounding therapies that could retain neuroplasticity-enhancing effects while avoiding the hallucinogenic effects associated with traditional psychedelic compoun
Company Proposes New Regulatory Approaches for Neuroplastogens
Under FDA Docket No. FDA-2026-N-7542, Clearmind recommended that regulators consider potential new approaches for therapies based on non-hallucinogenic neuroplastogens. The company highlighted the possibility of guidance supporting self-administration and at-home-potential treatment models, alongside streamlined regulatory pathways and broader clinical trial access. Clearmind also pointed to the potential use of Breakthrough Therapy Designation and other regulatory mechanisms that could support development and access to therapies addressing significant unmet needs. According to the company, eliminating hallucinogenic effects could potentially reduce the need for intensive supervised dosing environments associated with certain traditional psychedelic treatments, with implications for treatment scalability and cost.
Yale and Johns Hopkins Studies Support Development Strategy
Clearmind’s recommendations reference clinical research conducted at Yale University and Johns Hopkins University, where the company said studies have generated data supporting further investigation of non-hallucinogenic neuroplastogenic compounds. Clearmind is developing these compounds as potential treatments designed to enhance neuroplasticity without producing the hallucinogenic effects of legacy psychedelics. The company also called for additional research collaborations involving U.S. federal agencies, including the Department of Veterans Affairs, Department of War and Department of Health and Human Services, to explore safer, potentially at-home treatment approaches for AUD and other indications. Clearmind said these efforts could help generate additional evidence around patient access, treatment delivery and the clinical utility of its emerging therapeutic approach.
Advertisement
Clearmind Expands Federal Engagement and Clinical Strategy
The FDA submission follows several recent interactions between Clearmind and U.S. federal agencies concerning psychedelic-derived therapies. In April, the company said it welcomed an executive order addressing accelerated medical treatment pathways for serious mental illness. In July, Clearmind responded to an HHS request for information under the Great American Recovery Initiative, highlighting MEAI and non-hallucinogenic neuroplastogens for AUD. On September 14, the company’s Chief of Global Impact, Mary-Elizabeth Gifford, briefed an FDA-convened federal panel on patient access and insights from clinical trials at Yale and Johns Hopkins. Clearmind said its latest submission continues its effort to participate in regulatory discussions while advancing clinical development of non-hallucinogenic neuroplastogen-based medicines for addiction and other neuropsychiatric conditions.
Source::Clearmind Medicine press release
